DOUBLE-BLIND, RANDOMISED, ACTIVE AND PLACEBO CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SKIN TOLERABILITY AND PHARMACOLOGICAL ACTIVITY OF A NEW TOPICAL COMPOUND (UR-1505 0.5%, 1% AND 2%) IN PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS

Trial Profile

DOUBLE-BLIND, RANDOMISED, ACTIVE AND PLACEBO CONTROLLED STUDY TO ASSESS THE CLINICAL EFFICACY, SKIN TOLERABILITY AND PHARMACOLOGICAL ACTIVITY OF A NEW TOPICAL COMPOUND (UR-1505 0.5%, 1% AND 2%) IN PATIENTS WITH MILD TO MODERATE ATOPIC DERMATITIS

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs UR 1505 (Primary) ; Tacrolimus
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Palau Pharma
  • Most Recent Events

    • 31 Jul 2015 New trial record
    • 07 Jul 2015 Status changed from recruiting to completed according to results published in the Clinical Therapeutics.
    • 07 Jul 2015 Results published in the Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top